Eli Lilly & Co.’s third quarter sales gains were driven largely by new products that are facing high-profile competition and reimbursement pressures, but the company says it is on track to meet revenue goals through 2020 even if the potential Alzheimer’s blockbuster therapy solanezumab fails in the Phase III EXPEDITION-3 clinical trial expected to report later this year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?